Aether Industries
Growing CEM contracts & steady LSM demand
Start with the part which makes this company a bit different from others ie R&D
Key R&D Themes
Deep chemistry capabilities – process chemistry & scale-up strengths rather than discovery.
Strong pipeline conversion rate – high success from lab → pilot → commercial.
Custom Synthesis & Contract Manufacturing (CEM) focus as a core R&D monetization engine.
Multi-step complex chemistries creating high switching cost for customers.
R&D-led margin profile – premium pricing due to proprietary processes.
Customer-linked R&D engagements with long visibility & potential annuity revenues.
Specialization in niche chemistries – photochlorination, hydrogenation, ethoxylation, advanced polymers, etc.
New product pipeline feeding future revenue streams.
Application-centric R&D for end industries like pharma, agro, polymers & material science.
Technology scale-up as differentiator – ability to convert gram-scale chemistry into multi-MT production.
Why R&D is Critical to Aether’s Thesis
Aether’s revenue mainly comes from its three business divisions such as largescale manufacturing, CRAMS, and contract/exclusive manufacturing. Out of these three business divisions, CRAMS has the highest EBITDA margin of 70%, contract manufacturing’s EBITDA margin is around 32% and large-scale manufacturing has the lowest margin of around 25-28%
After trading at lofty valuations above 100x earnings, the P/E multiple has normalised to nearly 50x. With major capex projects set to turn productive, the business may enter a high-growth phase by FY27, potentially triggering a rerating.
Segmental breakup ( By end user industry)
Aether is moving from “chemical intermediates for pharma & agro” → to
High-margin engineered chemical solutions for
🔹 Oil & Gas
🔹 High performance polymers
🔹 Electronic & material science applications
🔹 Global contract manufacturing
For the first time, CEM has contributed more than the LSM business vertical and CRAMS and CEM combined have contributed more than 50% of the sales.” Management goal: “CRAMS and CEM together will contribute 60%-70% of the sales in the next two years period.”
CEM
Long-term exclusive contracts where Aether is often the sole supplier.
For capex-intensive businesses like Aether, gross block growth today = revenue growth tomorrow.
Gross Block Trend from the Data Provided
CWIP (Capital Work In Progress)
Aether is clearly front-loading capex aggressively. Capex growth far exceeds revenue growth so far, meaning a surge in revenue is yet to be realized.
Aether claims 2x asset turnover
Current revenues: ~₹850–1,100 Cr range
Fixed asset block potentially usable soon: ₹1,800 Cr+ (Gross block + CWIP getting capitalized)
Potential achievable revenue at 2x turnover: ₹3,600–₹4,000 Cr
Compared to FY25 revenue of ₹850–1,100 Cr → 4x scaling runway
Bull Case Interpretation
Management building for future scale, not near-term optics
Revenue & profitability will lag capex → inflection when plants start production
Capex discipline suggests visibility of long-term customer commitments
Risk View
If demand or ramp-up is delayed, returns on capex can lag → temporary ROE compression
Capital-intensive + fire incident history → execution monitoring is essential
Aether’s rapidly increasing gross block + very high CWIP indicates the company is entering a capacity monetization phase.
We are at the point where:
Capex cycle is peaking
Revenue scaling cycle is about to begin
This echoes the thesis:
Aether is transitioning from a pharma/agro-dependent intermediate maker to a global specialty chemical innovator — powered by long-term contracts, demand-led capex and export growth
If execution stays on track, medium-term returns may compound significantly as:
Capex productivity → higher asset-turnover
Mix shift → higher EBITDA margin
Earnings catch up → rising ROE from 7.8% to projected 14%
Few things to get some knowledge upon for next set of points i will try to cover.
Life sciences: chemicals used by pharma, agrochemicals, biotech, medical devices
Non-life sciences: everything else — industrial chemicals, performance materials, oil & gas, electronics
Material sciences: a subset of non-life sciences focused on materials (plastics, polymers, composites, additives) used in high-end applications
Now that out of the way.
Site-3++ represents a strategic milestone, now entirely dedicated to an contract / exclusive manufacturing for a leading global material science company — a project nurtured over four years from laboratory development to full-scale commercial production
source : AR 2025
source : Concall Q2FY26
source : Concall Q1FY26
Guidances given by Aether Industries Ltd. in the Q2 FY26 concall:
EBITDA margin: Sustained around 30% (“30% margin is surely sustainable”).
PAT margin: Guided around 19–20% in the medium term (despite mix shift to higher-value segments) due to rising depreciation & finance costs.
Growth trajectory: Comfortable with ~25% growth going forward for revenue.
Mix shift: Expecting CRAMS + CEM together to contribute 60–70% of sales over the next two years.
Working capital: Targeting to bring ~140 days working capital cycle in FY27 (from ~149 days at Sep-30-25).
Asset turns: Company-level target of 1.5×–1.75× on gross block once the new capacity stabilises.
Capex funding: No further equity raise planned for next 5-7 years; growth via internal accruals + debt.
Commissioning timelines: Site-3++ (Milliken) in Q4 FY26; first two production blocks of Site-5 by start of Q4 FY26 (or Dec-25) with meaningful ramp from FY27.
Very good summary. Didn’t realise you are also tracking!